Company profile
Seagen, a wholly owned subsidiary of Pfizer
Privately held: no public share price (Pfizer's acquisition closed 14 Dec 2023; SGEN was delisted from Nasdaq and Seagen is now a wholly-owned Pfizer subsidiary with no independent traded equity. Parent: Pfizer Inc. (NYSE: PFE). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.sec.gov/Archives/edgar/data/1060736/000119312523157991/d502779dex991.htm]) · United States
Assets
(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-L1Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 3 | Integrin beta-6 (ITGB6)Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | CEACAM5Antibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.